Preview

Медицинский алфавит

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Головная боль при ревматических заболеваниях

https://doi.org/10.33667/2078-5631-2020-11-22-31

Полный текст:

Аннотация

Головная боль – частый, но не всегда адекватно диагностируемый симптом ревматических болезней. Головная боль может быть проявлением внутричерепной патологии (воспалительный процесс, тромбоз и др.) или же экстракраниального заболевания, например воспалительного или дегенеративного процесса анатомически близких структур (орган зрения, шея, придаточные пазухи носа и др.). Кроме того, у пациентов с ревматическими болезнями могут быть такие же причины первичной головной боли, как и в популяции в целом. В то время как первичная головная боль обычно является доброкачественной по течению, другие варианты головной боли могут быть признаками дебюта болезни или ее прогрессирования, а также развития осложнений. Важным является понимание как причин головной боли, связанной с ревматическими болезнями, так и механизмов ее развития, что позволит улучшить диагностику и лечение ревматических болезней в целом.

Об авторах

А. Д. Мешков
ГБУЗ г. Москвы «Московский клинический научно-практический центр имени А. С. Логинова» Департамента здравоохранения г. Москвы
Россия

к. м. н., врач-ревматолог

 г. Москва



Г. В. Лукина
ГБУЗ г. Москвы «Московский клинический научно-практический центр имени А. С. Логинова» Департамента здравоохранения г. Москвы
Россия

д. м. н., проф., зав. научно-исследовательским отделом ревматологии, рук. Московского городского ревматологического центра

 г. Москва



П. И. Новиков
ФГАОУ ВО «Первый Московский государственный медицинский университет имени И. М. Сеченова (Сеченовский университет)» Минздрава России
Россия

к. м. н., зав. ревматологическим отделением клиники ревматологии, нефрологии и профпатологии им. Е. М. Тареева

 г. Москва



К. Е. Федоров
Ревматологический центр католической клиники «Сент-Элизабет» ГмбХ
Германия

врач-ревматолог

г. Херне



Список литературы

1. Arend W. et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. // Arthritis Rheum. 1990.

2. Jennette J. et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. // Arthritis Rheum. 1994.

3. Гуляев С.В., Мешков А. Д., Новиков П. И., Моисе- ев С. В. Ф.В.В. Гигантоклеточный артериит как при- чина лихорадки неясного генеза у пожилых // Те- рапевтический архив. 2014. № 12 (том 2). P. 47–51.

4. Новиков П.И., Семенкова Е. Н. М.С.В. Современная номенклатура системных васкулитов // Клиничес- кая фармакология и терапия. 2013. № 1. P. 70–74.

5. Birnbaum J H. D. Primary angiitis of the central nervous system. // Arch Neurol. 2009.

6. Gerretsen P., Kern R. Z. Reversible cerebral vasoconstriction syndrome or primary angiitis of the central nervous system? // Can J Neurol Sci. 2007.

7. Lie J. T. Primary (granulomatous) angiitis of the central nervous system: A clinicopathologic analysis of 15 new cases and a review of the literature // Human Pathology. 1992.

8. Ducros A. Reversible cerebral vasoconstriction syndrome // The Lancet Neurology. 2012.

9. Calabrese L.H., Gragg L. A., Furlan A. J. Benign angiopathy: A distinct subset of angiographically defined primary angiitis of the central nervous system // J. Rheumatol. 1993.

10. Hajj-Ali R.A. et al. Primary angiitis of the CNS // The Lancet Neurology. 2011.

11. M.A. G.-G. et al. Giant cell arteritis: Epidemiology, diagnosis, and management // Curr. Rheumatol. Rep. 2010.

12. Мухин Н.А., Мешков А. Д., Новиков П. И., Моисеев С. В., Щербакова В. Д., Манукова В. А., Исмаилова Д. С., Эксаренко О. В., Перова Ю. А., Казарина В. В. Ф.В.В. Гигантоклеточный артериит: клинические проявления и методы ранней диагностики // Клиническая фармакология и терапия. 2015. № 3. P. 79–85.

13. Cullen J.F., Coleiro J. A. Ophthalmic complications of giant cell arteritis // Survey of Ophthalmology. 1976.

14. Niederkohr R.D., Levin L. A. A Bayesian analysis of the true sensitivity of a temporal artery biopsy // Investig. Ophthalmol. Vis. Sci. 2007.

15. Younge B.R. et al. Initiation of Glucocorticoid Therapy: Before or after Temporal Artery Biopsy? // Mayo Clin. Proc. 2004.

16. Achkar A.A. et al. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? // Ann. Intern. Med. 1994.

17. Nahas S. J. Headache and temporal arteritis: When to suspect and how to manage // Curr. Pain Headache Rep. 2012.

18. Мешков А.Д., Новиков П. И., Фомин В. В. М.С.В. Ги- гантоклеточный артериит: трудности диагностики и методы лечения // Клиническая фармакология и терапия. 2014. № 2. P. 55–60.

19. Schmidt W. et al. Color duplex ultrasonography in the diagnosis of temporal arteritis. // N. Engl. J. Med. 1997.

20. Karassa F.B. et al. Meta-analysis: Test performance of ultrasonography for giant-cell arteritis // Annals of Internal Medicine. 2005.

21. Arida A. et al. The diagnostic value of ultrasonography- derived edema of the temporal artery wall in giant cell arteritis: A second meta-analysis // BMC Musculoskelet. Disord. 2010.

22. Black R. et al. The use of temporal artery ultrasound in the diagnosis of giant cell arteritis in routine practice // Int J Rheum Dis. 2013.

23. A. Meshkov, O. Eksarenko, D. Ismailova, P. Novikov, S. Moiseev V. F. The diagnostic value of ultrasound examination of ocular and orbital blood flow in patients with giant-cell arteritis // Ann. Rheum. Dis. 2015. Vol. 74 (Suppl. 2). P. 523.

24. Bley T.A. et al. Diagnostic value of high-resolution MR imaging in giant cell arteritis // AJNR Am. J. Neuroradiol. 2007.

25. Schmidt W. A. Imaging in vasculitis // Best Pract. Res. Clin. Rheumatol. 2013.

26. Brodmann M. et al. The role of 2–18F-fluoro‑2-deoxy- D-glucose positron emission tomography in the diagnosis of giant cell arteritis of the temporal arteries // Rheumatology. 2004.

27. Besson F.L. et al. Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis // Eur. J. Nucl. Med. Mol. Imaging. 2011.

28. Манукова В.А., Асланиди И. П., Мухортова О. В., Катунина Т. А., Рудас М. С., Новиков П. И. М.А.Д. Позитронно-эмиссионная томография с 18F-фтордезоксиглюкозой в ранней диагностике гигантоклеточного артериита // Клиническая фармакология и терапия. 2016. № 5. P. 34–39.

29. Novikov P.I., Meshkov A. D., Moiseev S. V. Positron emission tomography in giant cell arteritis: a new diagnostic tool? // Annals of the rheumatic diseases. 2014.

30. A. Meshkov, P. Novikov, I. Smitienko, S. Moiseev V. F. Spectrum of vascular involvement in PET-confirmed GCA without cranial manifestations // Nephron. 2015. Vol. 129 (suppl.) P. 176–177.

31. González-Gay M.A. et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. // Arthritis Rheum. 1998.

32. Hunder G.G. et al. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. // Ann. Intern. Med. 1975.

33. Mazlumzadeh M. et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial // Arthritis and rheumatism. 2006.

34. Bienvenu B. et al. Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA) // Rev. Med. Interne. 2016.

35. Villa-Forte A. Giant cell arteritis: Suspect it, treat it promptly // Cleveland Clinic Journal of Medicine. 2011.

36. González-Gay M. et al. Treatment of giant cell arteritis // Biochemical Pharmacology. 2019.

37. Moiseev S., Novikov P., Meshkov A. S. I. Biological agents for giant cell arteritis: treat to target // Ann Rheum Dis. 2016. P. Sep; 75 (9): e58.

38. Berger C. et al. High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition // Rheumatology. 2009.

39. Hall S. et al. Takayasu arteritis. A study of 32 North American patients. // Medicine (Baltimore). 1985.

40. Brunner J. et al. Takayasu arteritis in children and adolescents // Rheumatology. 2010.

41. Schmidt J. et al. Diagnostic features, treatment, and outcomes of Takayasu arteritis in a US cohort of 126 patients // Mayo Clin. Proc. 2013.

42. Rossi C.M., Di Comite G. The clinical spectrum of the neurological involvement in vasculitides // Journal of the Neurological Sciences. 2009.

43. Keser G., Direskeneli H., Aksu K. Management of Takayasu arteritis: A systematic review // Rheumatology (United Kingdom). 2014.

44. Rosenberg M.R. et al. Central nervous system polyarteritis nodosa // West. J. Med. 1990.

45. Watts R.A., Carruthers D. M., Scott D. G.I. Epidemiology of systemic vasculitis: Changing incidence or definition? // Semin. Arthritis Rheum. 1995.

46. Seo P., Stone J. H. The antineutrophil cytoplasmic antibody-associated vasculitides. // Am. J. Med. 2004.

47. Chhetri M.K., Bhattacharya A. K., Kumar T. Headache in rheumatological disorders // J. Indian Med. Assoc. 2011.

48. Новиков П.И., Зыкова А. С., Смитиенко И. О. М.С.В. Лечение АНЦА-ассоциированных васкулитов: рекомендации EULAR/ERA-EDTA 2016 года // Клиническая фармакология и терапия. 2017. № 1. P. 80–87.

49. Idil A. et al. The prevalence of Behçet’s disease above the age of 10 years. The results of a pilot study conducted at the Park Primary Health Care Center in Ankara, Turkey. // Ophthalmic Epidemiol. 2002.

50. Azizlerli G. et al. Prevalence of Behcet’s disease in Istanbul, Turkey. // Int. J. Dermatol. 2003. 51. Siva A., Saip S. The spectrum of nervous system involvement in Behçet’s syndrome and its differential diagnosis // Journal of Neurology. 2009.

51. Saip S. et al. Headache in Behçet’s syndrome // Headache. 2005.

52. Hatemi G. et al. EULAR recommendations for the management of Behçet disease // Ann. Rheum. Dis. 2008.

53. Kotake S. et al. Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. // Ophthalmology. 1999.

54. Kötter I. et al. CNS involvement occurs more frequently in patients with Behçet’s disease under cyclosporin A (CSA) than under other medications – Results of a retrospective analysis of 117 cases // Clin. Rheumatol. 2006.

55. Kato Y. et al. Central nervous system symptoms in a population of Behçet’s disease patients with refractory uveitis treated with cyclosporine A // Clinical and Experimental Ophthalmology. 2001.

56. Cordato D.J. et al. Prevalence of positive syphilis serology

57. and meningovascular neurosyphilis in patients admitted with stroke and TIA from a culturally diverse population (2005–09) // J. Clin. Neurosci. 2013.

58. Zhang H.L. et al. Clinical spectrum of neurosyphilis among HIV-negative patients in the modern era // Dermatology. 2013.

59. Ahmad N.M., Boruchoff S. E. Multiple cerebral infarcts due to varicella-zoster virus large-vessel vasculopathy in an immunocompetent adult without skin involvement // Clin. Infect. Dis. 2003.

60. Constantinescu C.S. et al. Association of varicella-zoster virus with cervical artery dissection in 2 cases [3] (multiple letters) // Archives of Neurology. 2000.

61. Gilden D. et al. Varicella zoster virus vasculopathies: diverse clinical manifestations, laboratory features, pathogenesis, and treatment // The Lancet Neurology. 2009.

62. Fukumoto S. et al. Subarachnoid hemorrhage and granulomatous angiitis of the basilar artery: Demonstration of the varicella-zoster-virus in the Basilar artery lesions // Stroke. 1986.

63. Kapoor S. Headache attributed to cranial or cervical vascular disorders // Curr. Pain Headache Rep. 2013.

64. Amaral T.N. et al. Neurologic involvement in scleroderma: A systematic review // Semin. Arthritis Rheum. 2013.

65. Kupersmith M.J. et al. Idiopathic hypertrophic pachymeningitis // Neurology. 2004.

66. Chan S.K. et al. IgG4-related sclerosing pachymeningitis: A previously unrecognized form of central nervous system involvement in IgG4-related sclerosing disease // Am. J. Surg. Pathol. 2009.

67. Wallace Z.S. et al. IgG4-related disease and hypertrophic pachymeningitis // Med. (United States). 2013.

68. Baughman R. et al. Design of A Case Control Etiologic Study of Sarcoidosis (ACCESS) // Journal of Clinical Epidemiology. 1999.

69. Rao D.A., Dellaripa P. F. Extrapulmonary manifestations of sarcoidosis // Rheumatic Disease Clinics of North America. 2013.

70. Hoitsma E., Drent M., Sharma O. P. A pragmatic approach to diagnosing and treating neurosarcoidosis in the 21st century // Current Opinion in Pulmonary Medicine. 2010.

71. Stern B. J. Neurological complications of sarcoidosis // Current Opinion in Neurology. 2004.

72. Vargas D.L., Stern B. J. Neurosarcoidosis: Diagnosis and management // Seminars in Respiratory and Critical Care Medicine. 2010.

73. Pawate S., Moses H., Sriram S. Presentations and outcomes of neurosarcoidosis: A study of 54 cases // QJM. 2009.

74. Scott T.F. et al. Aggressive therapy for neurosarcoidosis: Long-term follow-up of 48 treated patients // Arch. Neurol. 2007.

75. Marnane M. et al. Steroid-unresponsive neurosarcoidosis successfully treated with adalimumab // J. Neurol. 2009.

76. Pereira J. et al. Medically refractory neurosarcoidosis treated with infliximab // Intern. Med. J. 2011.

77. Santos E. et al. Treatment of refractory neurosarcoidosis with Infliximab // J. Neurol. Neurosurg. Psychiatry. 2010.

78. Sodhi M. et al. Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis // Respir. Med. 2009.

79. Muscal E., Brey R. L. Neurologic Manifestations of Systemic Lupus Erythematosus in Children and Adults // Neurologic Clinics. 2010.

80. Popescu A., H. Kao A. Neuropsychiatric Systemic Lupus Erythematosus // Curr. Neuropharmacol. 2011.

81. S. B. et al. Recurrent headache and MRI findings in systemic lupus erythematosus // Journal of the National Medical Association. 2008.

82. Barber C.E. et al. Posterior Reversible Encephalopathy Syndrome: An Emerging Disease Manifestation in Systemic Lupus Erythematosus // Semin. Arthritis Rheum. 2011.

83. Gatla N. et al. Posterior reversible encephalopathy syndrome in systemic lupus erythematosus. // J. Clin. Rheumatol. 2013.

84. Lai C.-C. et al. Clinical Features and Outcomes of Posterior Reversible Encephalopathy Syndrome in Patients With Systemic Lupus Erythematosus // Arthritis Care Res. (Hoboken). 2013.

85. Liu B. et al. Posterior reversible encephalopathy syndrome could be an underestimated variant of “reversible neurological deficits” in Systemic Lupus Erythematosus // BMC Neurol. 2012.

86. Kim J.-M. et al. Idiopathic intracranial hypertension as a significant cause of intractable headache in patients with systemic lupus erythematosus: a 15-year experience. // Lupus. 2012.

87. Abu-Shakra M. et al. Anticardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations. // Am. J. Med. 1995.

88. Danowski A. et al. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. // J. Rheumatol. 2009.

89. Widener H.L., Littman B. H. Ibuprofen-Induced Meningitis in Systemic Lupus Erythematosus // JAMA J. Am. Med. Assoc. 1978.

90. Ball J. Enthesopathy of rheumatoid and ankylosing spondylitis. // Ann. Rheum. Dis. 1971.

91. Stevens J.C. et al. Atlanto-axial subluxation and cervical myelopathy in rheumatoid arthritis // QJM. 1971.

92. Neva M.H. et al. Early and extensive erosiveness in peripheral joints predicts atlantoaxial subluxations in patients with rheumatoid arthritis // Arthritis Rheum. 2003.

93. Paimela L. et al. Progression of cervical spine changes in patients with early rheumatoid arthritis // J. Rheumatol. 1997.

94. Winfield J. et al. Prospective study of the radiological changes in hands, feet, and cervical spine in adult rheumatoid disease // Ann. Rheum. Dis. 1983.

95. Neva M.H. et al. Combination drug therapy retards the development of rheumatoid atlantoaxial subluxations // Arthritis Rheum. 2000.

96. Ramos-Remus C. et al. Frequency of atlantoaxial subluxation and neurologic involvement in patients with ankylosing spondylitis. // J. Rheumatol. 1995.

97. Nowatzky J. et al. The role of uric acid and other crystals in osteoarthritis // Current Rheumatology Reports. 2010.

98. Zhang W. et al. European league against rheumatism recommendations for calcium pyrophosphate deposition. Part I: Terminology and diagnosis // Ann. Rheum. Dis. 2011.

99. Fye K.H., Weinstein P. R., Donald F. Compressive cervical myelopathy due to calcium pyrophosphate dihydrate deposition disease: report of a case and review of the literature. // Arch. Intern. Med. 1999.

100. Lin S.H. et al. Cervical myelopathy induced by pseudogout in ligamentum flavum and retro-odontoid mass: A case report // Spinal Cord. 2006.

101. Salcman M., Khan A., Symonds D. A. Calcium pyrophosphate arthropathy of the spine: case report and review of the literature. // Neurosurgery. 1994.

102. Eross E.J., Dodick D. W., Nelson K. D. Orthostatic headache syndrome with CSF leak secondary to bony pathology of the cervical spine // Cephalalgia. 2002.

103. Khung S. et al. Skeletal involvement in Langerhans cell histiocytosis // Insights into Imaging. 2013.

104. Karmacharya P. et al. Recurrent case of ibuprofen-induced aseptic meningitis in mixed connective tissue disease // BMJ Case Rep. 2013.


Для цитирования:


Мешков А.Д., Лукина Г.В., Новиков П.И., Федоров К.Е. Головная боль при ревматических заболеваниях. Медицинский алфавит. 2020;1(11):22-31. https://doi.org/10.33667/2078-5631-2020-11-22-31

For citation:


Meshkov A.D., Lukina G.V., Novikov P.I., Fedorov K.E. Headache in rheumatic diseases. Medical alphabet. 2020;1(11):22-31. (In Russ.) https://doi.org/10.33667/2078-5631-2020-11-22-31

Просмотров: 40


ISSN 2078-5631 (Print)